Major CYP450 Polymorphism among Saudi Patients
- PMID: 32703145
- DOI: 10.2174/1872312814666200722122232
Major CYP450 Polymorphism among Saudi Patients
Abstract
Background: Cytochrome P450 (CYP) contributes to a huge collection of medicinal products' Phase I metabolization. We aimed to summarize and investigate the current evidence regarding the frequency of CYP2D6, CYP2C9, CYP2C19, and MDR1 in Saudi Arabia.
Methods: A computerized search in four databases was done using the relevant keywords. The screening process was done in two steps; title and abstract screening and full-text screening. Data of demographic and characteristics of included studies and patients were extracted and tabulated.
Results: Ten studies were eligible for our criteria and were included in this systematic review. The age of participants ranged between 17-65 years. Only two subjects showed PM phenotype of CYP2C19 in the Saudi population. The most frequent alleles were CYP2C19*1 (62.9%), CYP2C19*2 (11.2%-32%), and CYP2C19*17 (25.7%). The CYP2C19m1 was observed in 97 cases of extensive metabolizing (EM) phenotype CYP2C19. Concerning the CYP2C9, the most frequent alleles were CYP2C9*1 and CYP2C9*2, and the most frequent genotype was CYP2C9*1*1. The CYP2D6*41 allele and C1236T MDR1 were the most frequent allele in this population.
Conclusion: The current evidence suggests that Saudi resembled European in the frequency of CYP2C19, Caucasians in both the incidence of CYP2C9 and CYP2C19m1, and the absence of CYP2C19m2. The CYP2D6*41 allele frequency in Saudi is relatively high. We recommend further research to evaluate the basic and clinical relevance of gene polymorphism in such ethnicity.
Keywords: CYP2C19; CYP2C9; CYP2D6; Cytochrome P450 (CYP).; MDR1; Saudis; polymorphism.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.Fundam Clin Pharmacol. 2007 Aug;21(4):419-26. doi: 10.1111/j.1472-8206.2007.00510.x. Fundam Clin Pharmacol. 2007. PMID: 17635181
-
Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.Croat Med J. 2003 Aug;44(4):425-8. Croat Med J. 2003. PMID: 12950145
-
Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.Drug Metab Pers Ther. 2019 Dec 18;34(4):/j/dmdi.2019.34.issue-4/dmpt-2019-0020/dmpt-2019-0020.xml. doi: 10.1515/dmpt-2019-0020. Drug Metab Pers Ther. 2019. PMID: 32004143
-
CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: A systematic review.J Clin Pharm Ther. 2019 Aug;44(4):508-524. doi: 10.1111/jcpt.12835. Epub 2019 Apr 13. J Clin Pharm Ther. 2019. PMID: 30980418
-
Clinical pharmacogenetics and potential application in personalized medicine.Curr Drug Metab. 2008 Oct;9(8):738-84. doi: 10.2174/138920008786049302. Curr Drug Metab. 2008. PMID: 18855611 Review.
Cited by
-
Tacrolimus-Induced Neurotoxicity in Early Post-Liver Transplant Saudi Patients: Incidence and Risk Factors.Ann Transplant. 2022 May 17;27:e935938. doi: 10.12659/AOT.935938. Ann Transplant. 2022. PMID: 35578566 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources